Ten-year literature review of global endometrial ablation with the NovaSure® device
| Autor: | RJ Gimpelson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class medicine.medical_treatment Review lcsh:Gynecology and obstetrics law.invention Patient satisfaction Randomized controlled trial law menorrhagia Maternity and Midwifery medicine Prospective cohort study lcsh:RG1-991 Gynecology Pregnancy business.industry Anticoagulant endometrial ablation Obstetrics and Gynecology medicine.disease Surgery medicine.anatomical_structure Oncology Endometrial ablation abnormal uterine bleeding Amenorrhea NovaSure® Uterine cavity medicine.symptom business |
| Zdroj: | International Journal of Women's Health International Journal of Women's Health, Vol 2014, Iss default, Pp 269-280 (2014) |
| ISSN: | 1179-1411 |
| Popis: | Richard J Gimpelson Mercy Clinic, Minimally Invasive Gynecology, Department of Obstetrics and Gynecology, Mercy Hospital St Louis, St Louis, MO, USA Abstract: This review examines the peer-reviewed literature describing prospective studies that report amenorrhea rates, patient satisfaction, and surgical reintervention rates following the NovaSure® endometrial ablation procedure. A search of the English-language literature published from 2000 to 2011 was conducted using PubMed. Ten prospective studies, six single-arm NovaSure trials, and four randomized controlled trials comparing the NovaSure procedure with other global endometrial ablation modalities met the inclusion criteria and were reviewed. The follow-up periods ranged from 6 to 60 months. Amenorrhea rates for the NovaSure procedure ranged from 30.0% to 75.0%. Patients who reported being satisfied with the NovaSure procedure ranged from 85.0% to 94.0%. In randomized controlled trials with other global endometrial ablation modalities, amenorrhea rates at 12 months with the NovaSure procedure ranged from 43.0% to 56.0%, while other modalities ranged from 8% to 24%. In addition, this manuscript reviews the following: the NovaSure technology; use of the NovaSure procedure in the office setting; intraoperative and postoperative pain; effects on premenstrual syndrome (PMS); dysmenorrhea; special circumstances, including presence of uterine disease, history of cesarean delivery, coagulopathy, or use of anticoagulant medication; post-procedure uterine cavity assessment and cancer risk; contraception and pregnancy; and safety. Keywords: abnormal uterine bleeding, menorrhagia, endometrial ablation, NovaSure® |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|